Introduction
============

Psoriasis is a highly heterogeneous disease with a complex genetic background, and the strategy to stratify into subgroups is likely to be fruitful for fully understanding the spectrum of the disease. The underlying genetics may affect the age at onset, and separating psoriasis into early- and late-onset disease using 40 years as the divider has been useful ([@bib23]). Using this definition, early-onset psoriasis has been shown to have a higher degree of heritability and a higher prevalence of *HLA-C\*06:02* ([@bib23]; [@bib17]). However, onset before the age of 40 years has been reported in ∼75% of patients with psoriasis and thus this definition of early-onset comprises the majority of patients with psoriasis ([@bib43]). Nevertheless, most genetic studies use this classification and lack a more detailed stratification.

Other stratification attempts separate patients according to *HLA-C* status. Presence of the risk allele *HLA-C\*06:02* is claimed to be associated with earlier disease onset, more severe disease course, and a higher prevalence of the guttate phenotype ([@bib28]; [@bib17]). Nail and joint manifestations are reported to be more frequent in *HLA-C\*06:02*-negative patients ([@bib17]).

Onset of psoriasis in adolescence and early adulthood is common, and a potential impact of puberty has been discussed ([@bib3]; [@bib14]; [@bib41]; [@bib34]). However, before puberty the onset of psoriasis is more unusual and is estimated to occur in only 10% of patients before the age of 10 and in 2% before the age of 2 years ([@bib14]; [@bib13]). Children with psoriasis may differ in their clinical presentation compared with adults and a correct diagnosis may be delayed, which is a potential confounder when determining disease onset in this group ([@bib30]; [@bib9]).

*HLA-C\*06:02* is the candidate gene allele with the strongest association with psoriasis ([@bib10]; [@bib12]). Exactly how *HLA-C\*06:02* contributes to disease is, however, still unclear. A recent genome-wide association study reported evidence for a genetic interaction between the *HLA-C* and endoplasmic reticulum aminopeptidase 1 (*ERAP1*) genes (combined *P*=6.95 × 10^−6^), with the *ERAP1-*associated synonymous single-nucleotide polymorphism (SNP) (rs27524) affecting psoriasis susceptibility only in individuals carrying the *HLA-C* risk allele ([@bib40]). *ERAP1* has an important role in MHC class I peptide processing in the endoplasmic reticulum and has also been shown to be involved in shedding of proinflammatory cytokine receptors, altogether suggestive of a potential involvement in the pathogenesis of psoriasis ([@bib7]; [@bib22]; [@bib19]). Other nonsynonymous *ERAP1* SNPs have been shown to be associated with ankylosing spondylitis (rs30187, rs26653) and multiple sclerosis (rs30187) ([@bib4]; [@bib35]; [@bib18]). Altogether, these data suggest that *ERAP1* may be essential in regulating immunity.

Herein we present a cohort of psoriasis patients stratified for phenotype (plaque and guttate) and age at onset ([Table 1](#tbl1){ref-type="table"}). The age groups were chosen in an attempt to reflect biologically significant transitions. In particular, we aimed to explore the impact of puberty. Setting the limit for puberty at 10 years represents a stringent approach ([@bib33]). Herein we report a strong association of *ERAP1* SNP rs26653 not restricted to *HLA-C\*06:02-*positive individuals. Stratification for age at onset revealed that ERAP1 association was confined to cases with disease onset between 10 and 20 years (odds ratio (OR) 1.59, 95% confidence interval (CI): 1.28--1.98, *P*=0.00008), whereas prepubertal children with onset between 0 and 9 years lacked association (OR 1.24, 95% CI: 0.93--1.65, *P*=0.4). This work reveals striking genetic heterogeneity among patients with early-onset psoriasis and stresses the importance of detailed stratification in future genetic studies in psoriasis.

Results
=======

The association of *HLA-C\*06:02* varies with the age at disease onset in psoriasis
-----------------------------------------------------------------------------------

The established and strong association of *HLA-C\*06:02* with psoriasis was confirmed in our cases (OR 4.51, 95% CI: 3.81--5.3, *P*=4.9 × 10^−76^) ([Table 2](#tbl2){ref-type="table"}). For analysis of a possible effect of age at onset, we separated the cases into four groups ([Table 1](#tbl1){ref-type="table"}). The strongest association for *HLA-C\*06:02* was detected in the age group 10--20 years (OR 8.46, 95% CI: 6.65--10.77, *P*=1.3 × 10^−86^), which was significantly stronger than that in the groups 0--9 (OR 5.71, 95% CI: 4.19--7.79, *P*=1.2 × 10^−33^) and 21--40 (OR 5.52, 95% CI: 4.40--6.92, *P*=8.9 × 10^−58^) ([Table 3](#tbl3){ref-type="table"}). In the oldest group with onset of disease above 40 years, the association with HLA-C^\*^06:02 was significant, albeit much lower (OR 1.89, 95% CI: 1.45--2.46, *P*=9.1 × 10^−6^) than published data ([@bib1]). The distribution of plaque and guttate phenotypes was similar in the three younger age cohorts but more skewed toward plaque phenotype in the oldest group ([Table 1](#tbl1){ref-type="table"}).

Replication of association for *ERAP1* in psoriasis
---------------------------------------------------

The association of *ERAP1* in psoriasis was reported recently ([@bib40]; [@bib2]). We investigated three SNPs in the *ERAP1* gene ([Table 2](#tbl2){ref-type="table"}). Significant allelic association was found for rs26653 (OR 1.31, 95% CI: 1.16--1.48, *P*=0.00006) and rs30187 (OR 1.16, 95% CI: 1.03--1.30, *P*=0.02) in the total data set. No association was found for rs27524 (OR 1.10, 95% CI: 0.98--1.23, *P*=0.11) in the total data set ([Table 2](#tbl2){ref-type="table"}), although we did find association with rs27524 in the group with disease onset between 10 and 20 years (OR 1.28, 95% CI: 1.04--1.58, *P*=0.02) ([Table 3](#tbl3){ref-type="table"}).

Association with *ERAP1* is not dependent on *HLA-C\*06:02* and is confined to cases with disease onset between 10 and 20 years
-------------------------------------------------------------------------------------------------------------------------------

In contrast to previous findings, in which the association of *ERAP1* rs27524 was confined to individuals carrying the *HLA-C\*06:02* allele, the association with rs26653 was independent of *HLA-C\*06:02* in the total data set (*P*=0.001, OR 1.39 95% CI: 1.14--1.70) ([Table 4a](#tbl4a){ref-type="table"}). Association independent of *HLA-C\*06:02* with rs27524 and rs30187 was found only in the group with onset between 10 and 20 years ([Table 4b](#tbl4b){ref-type="table"}). No interaction between *ERAP1* (rs26653, rs30187, rs27524) and *HLA-C\*06:02* was detected, neither in the total data set ([Supplementary Table S1](#sup1){ref-type="supplementary-material"} online) nor in the significantly associated group with onset between 10 and 20 years (data not shown).

Stratification for age at onset as described above showed association for all three nonsynonymous *ERAP1* SNPs rs26653 (OR 1.59, 95% CI: 1.28--1.98, *P*=0.00008), rs30187 (OR 1.46, 95% CI: 1.18--1.80, *P*=0.0001), and rs27524 (OR 1.28, 95% CI: 1.04--1.58, *P*=0.02) in the group of patients with onset between 10 and 20 years. The association with *ERAP1* in the 10--20 age group was significantly stronger compared with all other age groups (rs26653; OR 1.28 95% CI: 1.01--1.62, *P*=0.04, rs30187; OR 1.30, 95% CI: 1.03--1.63, *P*=0.03). In the group with age at onset between 21 and 40 years, there was borderline association for rs26653 (OR 1.27, 95% CI: 1.05--1.54, *P*=0.05).

No significant difference in *ERAP1* association was found when we stratified for the clinical phenotypes, plaque or guttate ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"} online).

Discussion
==========

The present view within the field of psoriasis is that the earlier the onset of disease, the stronger the association with *HLA-C\*06:02* and the more severe the disease ([@bib17]). The data presented herein reveal a more complex scenario where patients with onset of psoriasis during adolescence (here 10--20 years) emerge as a distinct group compared with those with onset before puberty ([Figure 1](#fig1){ref-type="fig"}). Children with disease onset below the age of 10 years have a prevalence of *HLA-C\*06:02* similar to that of patients with adult onset (21--40 years) and lack association with *ERAP1*, whereas cases with onset of disease between 10 and 20 years have a significantly higher prevalence of *HLA-C\*06:02* irrespective of phenotype and also show a significant association with *ERAP1* ([Table 3](#tbl3){ref-type="table"}). These data indicate an age-dependent difference in the genetic background among patients with early onset of psoriasis. Keeping in mind the limited number of cases in each group, we believe that the stringent inclusion criteria and careful phenotyping by only a handful of dermatologists around the time of disease onset serve to reinforce the results. Whether these genetic differences will translate into clinical differences in terms of disease development, severity, and comorbidity profiles should be explored in future studies.

Obviously, any stratification involves simplification, but we believe that a cutoff at 10 years of age represents a valid approximation for puberty that constitutes a significant biological transition ([@bib33]). In patients with juvenile psoriatic arthritis a similar pattern of two distinct populations of early-onset disease was presented, one with a peak of onset around the age of 2--3 years and the other group with a peak of onset around 10--12 years. Genetic and clinical differences were detected between these groups of juvenile psoriatic arthritis patients ([@bib38]; [@bib37]). An additional study on juvenile arthritis showed subtype-specific association with *ERAP1* and *IL23R*, in which the enthesitis-related arthritis subtype associated with *ERAP1*, whereas juvenile psoriatic arthritis showed association with *IL23R* ([@bib24]). A recent study in a small group of childhood psoriasis patients, separating early and late onset at 18 years of age, showed results in accordance with the data presented herein, with a stronger association with *ERAP1* rs27524 in the group with onset of disease before 18 years ([@bib2]).

A peak of disease onset at puberty has been shown in cases of psoriasis, which is slightly earlier in girls than in boys ([@bib41]). The mechanisms underlying this increase are not known today. A possible effect of increased levels of sex hormones at puberty, in particular estrogens, which are known to promote keratinocyte proliferation via receptor-mediated mechanisms and also to influence inflammatory pathways, has been discussed ([@bib31]; [@bib25]). Other potential triggers may be different infectious panorama in different age groups.

The distribution of phenotypes in the present study reveals a relatively high proportion of the guttate subtype. This may in part be explained by the recruitment strategy, which has been described in detail ([@bib27]). In short, patients were recruited in association with onset of first psoriasis episode and the diagnosis verified by a trained dermatologist in a single center. In the majority of patients (77%) an associated streptococcal infection was confirmed. Earlier studies have shown a higher prevalence of *HLA-C\*06:02* in patients with guttate psoriasis ([@bib28]; [@bib17]). The distribution between phenotypes (plaque versus guttate) in prepubertal and postpubertal children was similar in our study ([Table 1](#tbl1){ref-type="table"}). Thus, differences in *HLA-C\*06:02* prevalence between prepubertal children and postpubertal children cannot be attributed to a higher percentage of the guttate phenotype in the latter group but was rather contributed by a larger percentage of plaque cases carrying *HLA-C\*06:02* in the 10--20-year age group.

As expected, cases with late onset of disease (above 40 years) had significantly lower association with *HLA-C\*06:02* and also lacked association with *ERAP1*, confirming that 40 years represents a biologically valid approximation for a genetically distinct subgroup of psoriasis.

This work replicates the association of *ERAP1* in psoriasis. We studied three SNPs in the *ERAP1* gene ([Table 2](#tbl2){ref-type="table"}). The SNPs rs26653 (Arg127Pro) and rs30187 (Arg528Lys) have been shown to be associated with ankylosing spondylitis (rs26653 and rs30187) and multiple sclerosis (rs30187) and showed association with psoriasis in the present study ([@bib21]; [@bib26]; [@bib35]; [@bib18]). In contrast to the previously reported synonymous SNP rs27524, these latter SNPs are nonsynonymous and have been shown to be functional, affecting the catalytic activity of the enzyme ([@bib16]; [@bib29]; [@bib11]). The lack of association with the synonymous *ERAP1* SNP rs27524 in our data set could be because of two reasons: (a) our associated group (age 10--20) comprises only 21% of our total cases, which may not be sufficient to reach significance. If we randomly reduce the number of cases in the other age groups so that the 10--20-year group would make up 36% of the total data set, comparable to data recently presented in [@bib2], the association with rs27524 would be significant in our study as well ([@bib2]). (b) There are too few individuals carrying two minor alleles as rs27524 follows a recessive model, meaning that two minor alleles are needed for risk ([Supplementary Table S2](#sup1){ref-type="supplementary-material"} online). The SNPs rs26653 and rs30187 on the other hand display an additive genotypic effect ([Supplementary Table S2](#sup1){ref-type="supplementary-material"} online). The finding of significant association with rs30187 strengthens this conclusion, as rs30187 and rs27524 are in linkage disequilibrium.

Thus, stratification for age at onset revealed a clear age-dependent association with *ERAP1* ([Table 3](#tbl3){ref-type="table"}). Surprisingly, in our cases, association with *ERAP1* was not restricted to individuals carrying *HLA-C\*06:02*, and patients negative for *HLA-C\*06:02* with the rs26653 minor allele show an OR of 1.39 (95% CI: 1.14--1.70, *P*=0.001) ([Table 4a](#tbl4a){ref-type="table"}). The additive effect of carrying the minor allele (C) for rs26653 in *HLA-C\*06:02-*positive patients was seen between GG/P and GC/P genotype groups ([Figure 2](#fig2){ref-type="fig"}). Calculations for additive interaction and multiplicative interaction with stratification for different phenotypic and genetic data did not reveal any interactions. At present, we cannot explain the discrepancy between our findings and published data on *ERAP1* association being dependent on *HLA-C\*06:02* ([@bib40]). In the latter publication, the authors applied typing of rs10484554 to determine *HLA-C* status, which is different from the present method, which captures only *HLA-C\*06* genotypes ([@bib32]). However, using rs10484554 in our study did not alter the results (not shown).

At present, the functional consequences of ERAP1 polymorphisms in psoriasis are unknown. ERAP1 has several functions. It may act as a "molecular ruler" clipping peptides for optimal HLA class I binding and presentation ([@bib36]; [@bib5]). Second, *in vitro* studies suggest that ERAP1 cleaves cytokine receptors off the cell surface, including tumor necrosis factor receptor I ([@bib6]), IL-1R2 ([@bib8]), and IL6Rα ([@bib7]). However, a recent study showed that the ERAP1 polymorphisms associated with ankylosing spondylitis did not influence the serum cytokine receptor levels in patients with ankylosing spondylitis ([@bib20]). The peptide-trimming function theoretically implies a biological interaction with HLA and has so far been thought to be causative for most of the effect in psoriasis. However, functional studies are lacking, and the importance of a "sheddase" function for ERAP1 in psoriasis and other inflammatory needs further exploration.

To investigate whether clinical subtype (plaque or guttate) influenced association with *ERAP1*, we stratified for phenotype. No significant difference was detected ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"} online).

In summary, we found that childhood psoriasis is a genetically heterogeneous group with significant differences between prepubertal and postpubertal disease onset. Prepubertal cases had a similar profile for *HLA-C* and *ERAP1* as the group with onset between 21 and 40 years, whereas the group with onset between 10 and 20 years emerges as a distinct cluster carrying the strongest genetic *HLA-*C and *ERAP1* association. In contrast to previous reports, the association with *ERAP1* (rs26653) was neither dependent on nor interacting with *HLA-C\*06:02*. Our work stresses the importance of detailed stratification for age at disease onset in further genetic and mechanistic studies in psoriasis. We do acknowledge the importance of replicating the present findings in a separate cohort of psoriasis patients. It will then be crucial to use a stringent clinical classification of the psoriasis diagnosis, which may be particularly difficult in children. In addition, reliable data on age at onset must be secured to avoid dilution of data.

Materials and Methods
=====================

Study population
----------------

All patients included in the study were examined and the diagnosis of psoriasis verified by dermatologists at the department of Dermatology, Karolinska University Hospital, Stockholm, Sweden. The study was approved by the Regional Committee of Ethics and conducted according to the Declaration of Helsinki Principles. Patients and controls gave their informed consent; for children younger than 18 years of age, consent was also obtained from their parents. For inclusion, patients needed to present with at least one typical psoriasis lesion at the time of examination. Scalp involvement and/or diaper rash alone was not regarded as diagnostic. Only patients categorized as having plaque or guttate psoriasis were enrolled in the study to minimize clinical heterogeneity ([Table 1](#tbl1){ref-type="table"}). Other more rare phenotypes were excluded. Disease severity ranged from mild to severe psoriasis, representing a cross-section of psoriasis patients. Healthy controls were recruited from the Dermatology (*n*=513) clinic at the Karolinska University Hospital and from the Epidemiological Investigation of Rheumatoid arthritis study (EIRA study) (*n*=1235) ([@bib39]). Only cases and controls of Caucasian origin based on ethnicity SNP genotyping were included ([@bib15]). Controls were matched for sex (59% female/41% male).

Genotyping
----------

Peripheral blood samples were collected and genomic DNA extracted by standard procedures. SNPs were selected on the basis of previous publications ([@bib19]; [@bib40]; [@bib42]). All SNPs were genotyped on a 7900HT Fast Real-Time PCR System Instrument by using allele-specific Taqman MGB probes labeled with fluorescent dyes FAM and VIC (Applied Biosystems), according to the manufacturer\'s protocols. Allelic discrimination was made with the ABI PRISM 7900HT SDS and the SDS 2.2.1 program (Applied Biosystems). Ten percent of the samples were run as duplicates to check for genotyping errors. *HLA-C\*06:02* typing was carried out as described and referred to as positive when the *HLA-C\*06:02* allele was present and negative when not present ([@bib32]). We studied three SNPs in the *ERAP1* gene, rs26653 (Arg127Pro), rs30187 (Lys528Arg), and rs27524 (UTR3′). rs27524 and rs30187 were in linkage disequilibrium (*r*^2^=0.75).

Statistical analysis
--------------------

Case--control analysis was performed to test genetic markers for susceptibility to psoriasis. Case--case analysis was used to compare frequencies of genetic markers in plaque and guttate phenotypes and for different age groups. Both case--control and case--case analyses were tested for allele frequency differences for the three *ERAP1* SNPs (rs26653 (Arg127Pro), rs30187 (Lys528Arg), and rs27524 (UTR3′)) and for the HLA-C genotype using logistic regression. Association between genetic markers and disease status was analyzed using PLINK v1.07 (Purcell, 2007, \#85). Association for *ERAP1* SNP rs26653 stratified for *HLA-C\*06:02* status and age, as well as independent association for *ERAP1* using patients negative for *ERAP1* and *HLA-C\*06:02* minor allele as the reference group, was calculated using R v2.15.0 with GLM (<http://www.r-project.org/>). We also used R v2.15.0 with GLM (<http://www.r-project.org/>) to test for interaction between *ERAP1* and *HLA-C\*06:02* using both additive and multiplicative modes. Hardy--Weinberg equilibrium was evaluated for each SNP using the *χ*^2^-test. Significant *P*-values were corrected for multiple testing using the adjust mode as implemented in PLINK v1.07 (Purcell, 2007 \#85).
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###### 

Click here for additional data file.

![**HLA-C\*06:02 carrier and noncarrier distribution in the whole sample set.** Frequency of HLAC^\*^06:02 allele in the different age-at-onset groups.](jid2012280f1){#fig1}

![**Association for ERAP1 SNP rs26653 stratified for HLA-Cw06 status and age.** Estimates of genotype effects were calculated using logistic regression in the R software package. Individuals with the low-risk genotypes for rs26653 GG and HLA-C^\*^06 NN were set as the baseline. The other genotype combinations were coded according to a series of dichotomous indicator variables. Odds ratios were derived by exponentiation of the relevant coefficient from the logistic regression.](jid2012280f2){#fig2}

###### Characteristics of participants

                                   **Age at onset**                                               
  -------------------------------- ------------------ ---------- ---------- ---------- ---------- ------------
  Women (%)                        58 (49)            112 (55)   137 (48)   216 (62)   523 (55)   1,026 (59)
  Mean age at onset                5.4                14.9       31.0       56.8       33.9        
  Plaque phenotype (%)             96 (81)            157 (77)   201 (71)   309 (89)   763 (80)    
  Plaque phenotype HLA-Cw06 (%)    44 (46)            104 (66)   84 (42)    55 (17)    287 (38)    
  Guttate phenotype (%)            23 (19)            46 (23)    82 (29)    40 (11)    191 (20)    
  Guttate phenotype HLA-Cw06 (%)   19 (83)            38 (83)    69 (84)    25 (57)    151 (79)    

Abbreviation: *N*, number of subjects.

###### Markers analyzed in *ERAP1* and *HLA-C\*06* as well as allelic associations

                                                                                   **MAF**   **All cases**                   
  --- ------- ------------------------------------ ------------- ----------- ----- --------- --------------- --------------- -------------------
  5   ERAP1   rs26653                              Exon 2        Arg127Pro   C/G   0.26      0.31            0.00006         1.31 (1.16--1.48)
  5   ERAP1   rs30187                              Exon 11       Lys528Arg   T/C   0.34      0.38            0.02            1.16 (1.03--1.30)
  5   ERAP1   rs27524                              3′ UTR        None        A/G   0.36      0.39            0.11            1.10 (0.98--1.23)
  6   HLA-C   rs10484554                           None coding   None        T/C   0.10      0.28            1.8 × 10^−65^   3.55 (3.06--4.13)
  6   HLA-C   Cw06:02[5](#t2-fn6){ref-type="fn"}                             P/N   0.07      0.24            4.9 × 10^−76^   4.51 (3.81--5.34)

Abbreviations: CI, confidence interval; ERAP, endoplasmic reticulum aminopeptidase 1; MAF, minor allele frequency; OR, odds ratio; UTR, untranslated region.

Data from [www.ensembl.org](http://www.ensembl.org).

Data from [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov).

Minor allele/major allele.

Adjusted *P*-value for five tests with Holm as implemented in PLINK adjust.

See [@bib32].

###### Allelic associations for *ERAP1* and *HLA-C* genes in psoriasis patients stratified for age at onset (case versus controls)

                **Age at onset**                                                                                                                                                    
  ------------- ------------------ --------------- ------------------- ------ --------------- -------------------- ------ --------------- ------------------- ------ -------------- -------------------
  rs26653       0.30               0.4             1.24 (0.93--1.65)   0.36   0.00008         1.59 (1.28--1.98)    0.31        0.05       1.27 (1.05--1.54)   0.30   0.1            1.21 (1.01--1.44)
  rs30187       0.39               0.4             1.20 (0.91--1.57)   0.43   0.0001          1.46 (1.18--1.80)    0.35          1        1.03 (0.85--1.24)   0.37   0.5            1.11 (0.93--1.31)
  rs27524       0.39               0.4             1.12 (0.86--1.47)   0.42   0.02            1.28 (1.04--1.58)    0.36          1        0.98 (0.81--1.18)   0.38   0.5            1.09 (0.92--1.29)
  rs10484554    0.33               2.5 × 10^−28^   4.66 (3.48--6.24)   0.42   2.9 × 10^−72^   6.65 (5.29--8.35)    0.31    4.6 × 10^−46^  4.25 (3.44--5.24)   0.15   0.0005         1.59 (1.25--2.02)
  HLA-Cw06:02   0.29               1.2 × 10^−33^   5.71 (4.19--7.79)   0.38   1.3 × 10^−86^   8.46 (6.65--10.77)   0.28    8.9 × 10^−58^  5.52 (4.40--6.92)   0.12   9.1 × 10^−6^   1.89 (1.45--2.46)

Abbreviations: CI, confidence interval; ERAP, endoplasmic reticulum aminopeptidase 1; MAF ca, minor allele frequency cases; OR, odds ratio.

Adjusted *P*-value for five tests with Holm as implemented in PLINK adjust.

###### Independent association of *ERAP1* SNP rs26653 and *HLA-C\*06* in all subjects

  **rs26653**   **HLA-C\*06**    ***P*-value**    **OR (95% CI)**
  ------------- --------------- --------------- -------------------
  GG            NN                     1                 1
  GC/CC         NN                   0.001       1.39 (1.14--1.70)
  GG            P                \<2 × 10^−16^   6.21 (4.73--8.14)
  GC/CC         P                \<2 × 10^−16^   7.17 (5.47--9.39)

Abbreviations: CI, confidence interval; ERAP, endoplasmic reticulum aminopeptidase 1; NN, negative for HLA-C^\*^06; OR, odds ratio; P, positive for HLA-C^\*^06; SNP, single-nucleotide polymorphism.

Generalized linear model as implemented in R software package. Individuals with the low risk genotype for rs26653 and HLA-C^\*^06 NN were set as baseline.

###### Independent association of *ERAP1* SNPs and *HLA-C\*06* in the age group 10--20

  **ERAP1 SNP**   **ERAP1 genotype**   **HLA-C\*06**    ***P*-value**     **OR (95% CI)**
  --------------- -------------------- --------------- --------------- ----------------------
  rs26653         GG                   NN                     1                  1
                  GC/CC                NN                   0.009        2.02 (1.19--3.43)
                  GG                   P                \<2 × 10^−16^   19.43 (11.55--32.66)
                  GC/CC                P                \<2 × 10^−16^   27.11 (16.35--44.95)
  rs30187         CC                   NN                     1                  1
                  TC/TT                NN                  0.0005        3.10 (1.64--5.87)
                  CC                   P                \<2 × 10^−16^   28.00 (14.26--54.96)
                  TC/TT                P                \<2 × 10^−16^   38.70 (20.63--72.58)
  rs27524         GG                   NN                     1                  1
                  GA/AA                NN                   0.002        2.68 (1.41--5.08)
                  GG                   P                \<2 × 10^−16^   30.10 (15.43--58.70)
                  GA/AA                P                \<2 × 10^−16^   33.96 (18.09--63.76)

Abbreviations: CI, confidence interval; ERAP, endoplasmic reticulum aminopeptidase 1; NN, negative for HLA-C^\*^06; OR, odds ratio; P, positive for HLA-C^\*^06; SNP, single-nucleotide polymorphism.

Generalized linear model as implemented in R software package. Individuals with risk alleles for respective *ERAP1* SNPs and *HLA-C\*06*.
